Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Eli Lilly

Eli Lilly
1876 FOUNDED
PUBLIC STATUS
35K-40K EMPLOYEES
LLY STOCK SYMBOL
75 INVESTMENTS
$116.81 SHARE PRICE (As of Thursday Closing)
Description

Eli Lilly is a pharmaceutical company with a focus on neuroscience, endocrinology, oncology, and immunology. Lilly's key products include Alimta for cancer; Forteo for osteoporosis; Jardiance, Trulicity, Humalog, and Humulin for diabetes; Taltz and Olumiant for immunology; and Cialis for erectile dysfunction.

Website
Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Stock Exchange
NYS
Primary Office
  • Lilly Corporate Center
  • Indianapolis, IN 46285
  • United States

+1 (317) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Eli Lilly’s full profile, request a free trial.

Eli Lilly Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$81.65 - $132.13 $113B $117.98 $6.31 15.2M 971M

Eli Lilly Financials Summary

In Thousands,
USD
TTM
31-Mar-2019
FY 2018
31-Dec-2018
FY 2017
31-Dec-2017
FY 2016
31-Dec-2016
Enterprise Value 131,686,312 128,273,471 97,337,859 84,741,092
Revenue 23,947,900 24,555,700 22,871,300 21,222,100
EBITDA 4,779,500 5,515,500 3,822,400 4,947,100
Net Income 6,256,200 3,232,000 (204,100) 2,737,600
Total Assets 38,006,800 43,908,400 44,981,000 38,805,900
Total Debt 15,965,100 12,770,900 13,647,100 10,305,200
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Eli Lilly Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Eli Lilly‘s full profile, request access.

Request full access to PitchBook

Eli Lilly Competitors (23)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Lundbeck Corporation Valby, Denmark 0000
000 000000 00000 Private Debt Financed Bresso, Italy 0000 000.00 000000000 000.00
0000000 Formerly VC-backed Boston, MA 0000 000000000
00000000 000000000 Failed Transaction (M&A) West Conshohocken, PA 00 000.00 000000&0
00000000000 000000 Private Equity-Backed Mexico City, Mexico 000.00 0000000000 000.00
To view this company’s complete list of competitors, request access »

Eli Lilly Investments & Acquisitions (75)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000000 0000000000 22-Apr-2019 000000000 00000 Biotechnology 000000 00000
0000 00000000 15-Feb-2019 000000000000000000 000 Pharmaceuticals 00000 00000
00000 00000000000 14-Dec-2018 000000000000000000 Drug Discovery 0000 000000
00000000 13-Nov-2018 00000 00000 00 0000 Biotechnology 0000 0000000
Dicerna Pharmaceuticals 29-Oct-2018 PIPE 00000 Pharmaceuticals
To view this company’s complete investment and acquisition history, request access »

Eli Lilly Exits (24)

Company Name Exit Date Exit Type Exit Size Status Buyers
00000000 13-Nov-2018 00000 00000 00 0000 Completed
  • 15 buyers
0000000 25-Jul-2018 00000 00000 00 00000 Completed
  • 20 buyers
0000000 19-Dec-2017 000000000 000 Completed
  • 000 00000
000000 000000 26-Jan-2015 000 000.00 Completed
  • 000 00000
Zosano Pharma 19-Aug-2010 Later Stage VC 00.00 Completed
  • 3 buyers
To view this company’s complete exits history, request access »

Eli Lilly Subsidiaries (8)

Company Name Industry Location Founded
ARMO BioSciences Biotechnology Redwood City, CA 2012
0000000 000000000 Biotechnology Montreal, Canada 0000
0000000 0000000000 Pharmaceuticals Cambridge, MA 0000
00000 0000 0000000 Venture Capital Shanghai, China 0000
00000 00000000 Corporate Venture Capital Indianapolis, IN 0000
To view this company’s complete subsidiary history, request access »

Eli Lilly Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Eli Lilly‘s full profile, request access.

Request full access to PitchBook

Eli Lilly Executive Team (60)

Name Title Board
Seat
Contact
Info
David Ricks Chairman & Chief Executive Officer
Christi Shaw Senior Vice President and President, Lilly Bio-Medicines
Enrique Conterno Senior Vice President & President, Lilly Diabetes
Joshua Smiley Senior Vice President & Chief Financial Officer
Melissa Barnes Senior Vice President, Enterprise Risk Management and Chief Ethics and Compliance Officer

23 Former Executives

You’re viewing 5 of 60 executives. Get the full list »

Eli Lilly Board Members (7)

Name Representing Role Since Contact
Info
00000 00000 Eli Lilly Chairman & Chief Executive Officer 000 0000
00000 000000 Self Chairman, Directors and Corporate Governance Committee 000 0000
0000 0000000 Self Chairman, Finance Committee 000 0000
00000 000000 Self Board Member 000 0000
00000 0000000 Self Board Member 000 0000

2 Former Board Members

You’re viewing 5 of 7 board members. Get the full list »